India Trials Scenario: Leaders From Novartis, IQVIA, PwC Signal Winds Of Change
Executive Summary
Leaders from Novartis, IQVIA and PwC discuss the ground situation for trials in India as regulatory reforms, improved infrastructure and clinical expertise provide opportunities. Potential in areas like orphan diseases and tips for peer Amgen on getting trials going in India were among other highlights.
You may also be interested in...
After Long Regulatory Run, Sanofi’s Dupixent Set To Transform India AD Market
Sanofi has received a go-ahead in India for dupilumab in atopic dermatitis with a trial waiver. An India-specific price, local real-world effectiveness and safety study and compelling data are expected to give it an edge over competition in the wings, including Pfizer’s Cibinq.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: novel BMS drug shows promise in IPF; Novo’s oral semaglutide compares well with injectable in weight loss; Teva looks to innovative brands to return to growth; US setback for Intercept’s NASH drug; and India’s improving environment for clinical trials.
Big Pharma R&D Chiefs On IRA’s Unintended Casualty, Product Life Cycle Compression
R&D heads of Takeda, Amgen, Lilly and Novartis discuss some of the tectonic forces shaping the biopharma sector and the unintended consequences of the IRA on small molecule innovation. Advances in the neurodegenerative diseases segment amid impressive data from donanemab was another key talking point.